Recombinant Nipah virus/NiV F/Fusion glycoprotein F0 Protein, C-His

Catalog #: EVV08101 Specific References (0) DATASHEET

Bioactivity for Recombinant Nipah virus/NiV F/Fusion glycoprotein F0 Protein, C-His ?>

Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Expression system: Mammalian Cells

Accession: Q9IH63

Protein length: Ile27-Ser493

Overview

Catalog No.

EVV08101

Expression system

Mammalian Cells

Species

Nipah virus (NiV)

Protein length

Ile27-Ser493

Predicted molecular weight

57.71 kDa

Nature

Recombinant

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

Q9IH63

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Fusion glycoprotein F0, Protein F, Fusion glycoprotein F2, Fusion glycoprotein F1, F

Note

For research use only.

Data Image

SDS-PAGE

SDS PAGE for Recombinant Nipah virus/HeV F/Fusion glycoprotein F0 Protein
Bioactivity

C) The F-specific IgG antibodies and NAs induced by the pVAX1-F vaccine regimens were detected by ELISA and pseudovirus neutralization assay. Sera were collected at different times (2, 5, 8, 10, and 16 weeks) after the first immunization from each group. The dashed line represents the lower limit of detection (20 x dilution) (control group n = 3, vaccination group n = 6). (D) The F-specific IgG antibodies and NAs detected by ELISA and the pseudovirus neutralization assay in AdC68-F and pVAX1-F/AdC68-F vaccine regimens. The sera were collected at different times (2, 4, 6, 10, 14, 18, 22, 28, 32, 36, and 40 weeks) after the last immunization (control group n = 3, vaccination group n = 6). The F-specific IgG antibodies (IgG, upper) and neutralization antibodies (NAs, lower) are shown. The dashed line represents the lower limit of detection (25 x dilution). Data are shown as the mean ± SEM. Statistical significance was determined by 1-way ANOVA with Tukey's multiple-comparison test. NS, not significant. NiV F protein (AntibodySystem, EVV08101) was diluted in coating buffer (Solarbio, C1055) at a concentration of 2 μg/mL and then plated in high-bind ELISA plates (Corning) at 100 μL in each well.
Data sourced from citation (PMID: 37917215)
Bioactivity

(B) F-specific IgG induced by the vaccine regimens. All 3 vaccine regimens induced high levels of IgG antibodies, and the titers of IgG were elevated with increasing immunization times (n = 6).
Data sourced from citation (PMID: 37917215)

References

Datasheet

Document Download

Recombinant Nipah virus/NiV F/Fusion glycoprotein F0 Protein, C-His.pdf

$ 480

Product specifications

100 μg 480 1 mg 2880

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here